These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2772 related articles for article (PubMed ID: 12600228)

  • 1. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
    Demetri GD
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
    Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
    Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal stromal tumours.
    Connolly EM; Gaffney E; Reynolds JV
    Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
    Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
    Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib.
    Mechtersheimer G; Egerer G; Hensel M; Rieker RJ; Libicher M; Lehnert T; Penzel R
    Virchows Arch; 2004 Feb; 444(2):108-18. PubMed ID: 14735360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of malignant gastrointestinal stromal tumours.
    Joensuu H; Fletcher C; Dimitrijevic S; Silberman S; Roberts P; Demetri G
    Lancet Oncol; 2002 Nov; 3(11):655-64. PubMed ID: 12424067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
    Wu PC; Langerman A; Ryan CW; Hart J; Swiger S; Posner MC
    Surgery; 2003 Oct; 134(4):656-65; discussion 665-6. PubMed ID: 14605627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
    van Oosterom AT; Judson I; Verweij J; Stroobants S; Donato di Paola E; Dimitrijevic S; Martens M; Webb A; Sciot R; Van Glabbeke M; Silberman S; Nielsen OS;
    Lancet; 2001 Oct; 358(9291):1421-3. PubMed ID: 11705489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
    Joensuu H
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():28-30. PubMed ID: 11831069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    Demetri GD; von Mehren M; Blanke CD; Van den Abbeele AD; Eisenberg B; Roberts PJ; Heinrich MC; Tuveson DA; Singer S; Janicek M; Fletcher JA; Silverman SG; Silberman SL; Capdeville R; Kiese B; Peng B; Dimitrijevic S; Druker BJ; Corless C; Fletcher CD; Joensuu H
    N Engl J Med; 2002 Aug; 347(7):472-80. PubMed ID: 12181401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours.
    Joensuu H; Dimitrijevic S
    Ann Med; 2001 Oct; 33(7):451-5. PubMed ID: 11680792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].
    Larsen JB
    Ugeskr Laeger; 2003 Sep; 165(37):3503-7. PubMed ID: 14531349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
    J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.
    Sanford M; Scott LJ
    Drugs; 2010 Oct; 70(15):1963-72. PubMed ID: 20883053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 139.